Back

SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections.

Rosenheim, J.; Gupta, R. K.; Thakker, C.; Mann, T.; Bell, L. C.; Broderick, C. M.; Madon, K.; Papargyris, L.; Dayananda, P.; Kwok, A. J.; Greenan-Barrett, J.; Wagstaffe, H. R.; Conibear, E.; Fenn, J.; Hakki, S.; Lindeboom, R. G.; Dratvia, L.; Lemetais, B.; Weight, C. M.; Venturini, C.; Kaforou, M.; Levin, M.; Kalinova, M.; Mann, A.; Catchpole, A.; Knight, J. C.; Nikolic, M. Z.; Teichmann, S. A.; Killingley, B.; Barclay, W.; Chain, B. M.; Lalvani, A.; Heyderman, R. S.; Chiu, C.; Noursadeghi, M.

2023-06-05 infectious diseases
10.1101/2023.06.01.23290819
Show abstract

Evaluation of host-response blood transcriptional signatures of viral infection have so far failed to test whether these biomarkers reflect different biological processes that may be leveraged for distinct translational applications. We addressed this question in the SARS-CoV-2 human challenge model. We found differential time profiles for interferon (IFN) stimulated blood transcriptional responses represented by measurement of single genes. MX1 transcripts correlated with a rapid and transient wave of type 1 IFN stimulated genes (ISG) across all cell types, which may precede PCR detection of replicative infection. Another ISG, IFI27, showed a delayed but sustained response restricted to myeloid peripheral blood mononuclear cells, attributable to gene and cell-specific epigenetic regulation. These findings were reproducible in diverse respiratory virus challenges, and in natural infection with SARS-CoV-2 or unselected respiratory viruses. The MX1 response achieved superior diagnostic accuracy in early infection, correlation with viral load and identification of virus culture positivity, with potential to stratify patients for time sensitive antiviral treatment. IFI27 achieved superior diagnostic accuracy across the time course of symptomatic infection. Compared to blood, measurement of these responses in nasal mucosal samples was less sensitive and did not discriminate between early and late phases of infection.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 2%
16.0%
2
JCI Insight
based on 63 papers
Top 0.4%
10.6%
3
Immunity
based on 11 papers
Top 0.1%
6.6%
4
Science Translational Medicine
based on 40 papers
Top 0.5%
4.9%
5
iScience
based on 74 papers
Top 0.4%
4.9%
6
Scientific Reports
based on 701 papers
Top 40%
4.7%
7
Nature
based on 58 papers
Top 1%
3.1%
50% of probability mass above
8
Cell Reports Medicine
based on 49 papers
Top 1%
2.9%
9
The Journal of Infectious Diseases
based on 137 papers
Top 3%
2.9%
10
Nature Medicine
based on 88 papers
Top 3%
2.9%
11
eLife
based on 262 papers
Top 12%
2.4%
12
Cell
based on 28 papers
Top 0.9%
2.4%
13
Clinical Infectious Diseases
based on 219 papers
Top 13%
1.9%
14
Nature Immunology
based on 14 papers
Top 0.7%
1.8%
15
Proceedings of the National Academy of Sciences
based on 100 papers
Top 7%
1.6%
16
Journal of Clinical Investigation
based on 50 papers
Top 2%
1.6%
17
Science Immunology
based on 15 papers
Top 0.6%
1.6%
18
Frontiers in Immunology
based on 140 papers
Top 4%
1.6%
19
eBioMedicine
based on 82 papers
Top 2%
1.6%
20
Science
based on 46 papers
Top 4%
1.4%
21
PLOS Pathogens
based on 35 papers
Top 1%
1.4%
22
Science Advances
based on 52 papers
Top 3%
1.2%
23
PLOS ONE
based on 1737 papers
Top 94%
0.8%
24
Journal of Infection
based on 64 papers
Top 6%
0.8%
25
EBioMedicine
based on 21 papers
Top 1%
0.8%
26
The Journal of Immunology
based on 19 papers
Top 2%
0.8%
27
Genome Medicine
based on 56 papers
Top 6%
0.8%
28
Cell Reports
based on 25 papers
Top 2%
0.7%
29
mBio
based on 34 papers
Top 3%
0.7%
30
Viruses
based on 79 papers
Top 7%
0.7%